Aclaris Therapeutics 주식 (NASDAQ: ACRS)

에 대한 최신 뉴스 Aclaris Therapeutics (NASDAQ:ACRS) 주식

Aclaris Therapeutics

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Analyst Color

Biotech

News

Upgrades

Health Care

Price Target

Contracts

Analyst Ratings

Movers

Trading Ideas

General

ACRS

월요일에 아클라리스 테라퓨틱스(NASDAQ:ACRS)는 바이오시온(Biosion Inc)과 TSLP 및 IL4R 모두에 대한 전임상 단계의 새로운 이중특이적 항체인 BSI-045B 및 BSI-502에 대한 전 세계 권리(중화권 제외)에 대한 독점 라이센스 계약을 체결했다. 이 회사의 주식은 화요일 46% 이상 급등했다.

아클라리스의 주식이 46% 이상 급등, 분석가들이 전략적 검토 후 새로운 모멘텀을 확인

Aclaris Therapeutics, Inc. - Common Stock

Aclaris Therapeutics Inc

Scotiabank analyst Louise Chen initiates coverage on Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) with a Sector Outperform rating and announces Price Target of $15.

Initiation

Scotiabank Initiates Coverage On Aclaris Therapeutics with Sector Outperform Rating, Announces Price Target of $15

Guidance

Aclaris Therapeutics Expects Cash Runway Into 2028

Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) reported quarterly losses of $(1.01) per share which missed the analyst consensus estimate of $(0.24) by 320.83 percent. The company reported quarterly sales of $9.21 million which beat the analyst consensus estimate of $2.11 million by 336.89 percent. This is a 47.58 percent decrease over sales of $17.57 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Aclaris Therapeutics Q4 2024 GAAP EPS $(1.01) Misses $(0.24) Estimate, Sales $9.21M Beat $2.11M Estimate

Aclaris Therapeutics Announced The Availability Of A New Publication Describing The Unique Properties Of Aclaris Therapeutics' ATI-2138, A Novel Investigational Covalent Inhibitor Of Interleukin-2-inducible T Cell Kinase And Janus Kinase 3 In Development For The Treatment Of Autoimmune And Inflammatory Diseases

HC Wainwright &amp; Co. analyst Raghuram Selvaraju upgraded Aclaris Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) from Neutral to Buy and a <a href="https://www.benzinga.com/quote/ACRS/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $20</a>. The stock gained after the rerating.
In a press release last month, Aclaris announced that it had entered into an exclusive license agreement with privately held Biosion, Inc. for worldwide rights (excluding Greater China) to BSI-045B, a potential best-in-class, clinical-stage, novel anti-TSLP monoclonal antibody, and BSI-502, a potential best-in-class, preclinical-stage, novel bispecific antibody directed against both TSLP and IL4R.
Despite recent advances in anti-TSLP and anti-IL4R therapies, there remains a substantial unmet need for more effective and convenient treatment options.
Also Read: <a target="_blank" href="https://www.benzinga.com/media/24/12/42631016/taiwan-semiconductor-expands-in-japan-sony-and-denso-among-first-customers" rel="noreferrer noopener">Taiwan Semiconductor Expands in Japan: Sony and Denso Among First Customers</a>
In a completed Phase 2a, single-arm, proof-of-concept trial conducted in the U.S. in 22 patients with moderate-to-severe atopic dermatitis, BSI-045B was observed to have a pharmacodynamic, safety, and efficacy profile that could position it as a potential best-in-class therapy.
BSI-045B is also being advanced in multiple Phase 2 studies in China by Biosion&#8217;s regional partner, targeting severe asthma and chronic rhinosinusitis with nasal polyps, accelerating the potential to show proof-of-concept across additional indications.
Selvaraju expects Aclaris to initiate multiple mid-stage clinical studies next year in the U.S. due to potential positive results from the Chinese trials. 
This should pave the way for registration programs in the coming years. From Selvaraju&#8217;s vantage point, BSI-045B could generate billions of dollars in sales across solely the U.S. and European Union markets in only chronic asthma and atopic dermatitis indications.
This candidate could reach the U.S. market in 2029 to treat chronic asthma and in 2030 for treating AD, with potential peak annual sales of roughly $9.8 billion. 
Selvaraju&#8217;s forecasts include pricing in the $30K range in the U.S. and the $10K range in Europe, roughly in line with net pricing for Dupixent (dupilumab), the most commercially successful of the currently-marketed anti-IL-4R monoclonal antibodies with estimated 2024 sales totaling roughly 13 billion euros. 
Selvaraju noted that an earlier-generation monoclonal antibody, the anti-IgE agent Xolair (omalizumab), generated sales approaching $4 billion in 2023. Selvaraju ascribed a 30% probability of approval to BSI-045B in chronic asthma and a 20% probability of approval to this candidate in AD.
Selvaraju projected fourth-quarter revenue of $2.9 million and EPS of $(0.10).
Price Action: ACRS stock is up 8% at $2.94 at last check Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42627181/blackberry-growth-hinge-on-iot-secure-communications-despite-valuation-concerns-analyst" target="_blank" rel="noreferrer noopener">BlackBerry Growth Hinge On IoT, Secure Communications Despite Valuation Concerns: Analyst</a></li>
</ul>
Photo: Gorodenkoff/Shutterstock.com

Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Raymond James analyst Buck Horne upgraded the rating for Weyerhaeuser Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WY#NYSE">WY</a>) from Market Perform to Outperform and announced a $32 price target. Weyerhaeuser shares closed at $27.50 on Friday. <a href="https://www.benzinga.com/quote/WY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. analyst Raghuram Selvaraju upgraded the rating for Aclaris Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) from Neutral to Buy and maintained the price target of $20. Aclaris Therapeutics shares closed at $2.72 on Friday. See how other analysts view this stock.</li>
<li>Piper Sandler analyst Crispin Love upgraded GCM Grosvenor Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCMG#NASDAQ">GCMG</a>) from Neutral to Overweight and raised the price target from $12.5 to $14. GCM Grosvenor shares closed at $11.75 on Friday. <a href="https://www.benzinga.com/quote/GCMG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst Buck Horne upgraded the rating for PotlatchDeltic Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCH#NASDAQ">PCH</a>) from Market Perform to Outperform and announced a $45 price target. PotlatchDeltic shares closed at $38.75 on Friday. <a href="https://www.benzinga.com/quote/PCH/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying WY stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="592" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23102908/image-191-1024x592.png" alt="" class="wp-image-704426" style="width:637px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23102908/image-191-1024x592.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23102908/image-191-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23102908/image-191-768x444.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23102908/image-191.png 1078w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></li>
</ul>

Markets

GCMG

This Weyerhaeuser Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday

HC Wainwright &amp; Co. analyst Raghuram Selvaraju upgrades Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) from Neutral to Buy and maintains the price target from $20 to $20.

HC Wainwright & Co. Upgrades Aclaris Therapeutics to Buy, Maintains Price Target to $20

<h3>Gainers</h3>
<ul>
<li>Sonoma Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNOA#NASDAQ">SNOA</a>) stock moved upwards by 26.4% to $3.26 during Tuesday's pre-market session. The company's market cap stands at $4.3 million. </li>
<li>Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) shares increased by 19.1% to $3.74. The company's market cap stands at $267.1 million. </li>
<li>Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) shares rose 15.74% to $10.0. The market value of their outstanding shares is at $544.0 million. The company's, Q3 earnings came out 4 days ago. </li>
<li>TFF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFFP#NASDAQ">TFFP</a>) shares rose 15.41% to $0.42. The company's market cap stands at $1.4 million. </li>
<li>HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares increased by 15.32% to $1.43. The company's market cap stands at $54.0 million. As per the press release, Q3 earnings came out 3 days ago. </li>
<li>Fresh2 Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRES#NASDAQ">FRES</a>) stock rose 14.36% to $1.1. The company's market cap stands at $26.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Apollomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLM#NASDAQ">APLM</a>) stock fell 16.3% to $0.16 during Tuesday's pre-market session. The market value of their outstanding shares is at $17.8 million. </li>
<li>Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) stock fell 12.31% to $67.5. The market value of their outstanding shares is at $13.0 billion. </li>
<li>Cytek Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTKB#NASDAQ">CTKB</a>) stock declined by 10.78% to $5.38. The market value of their outstanding shares is at $693.0 million. </li>
<li>Grifols (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) shares fell 10.42% to $8.26. The company's market cap stands at $5.6 billion. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares decreased by 9.8% to $0.26. The company's market cap stands at $1.4 million. As per the press release, Q3 earnings came out 3 days ago. </li>
<li>Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) stock decreased by 9.26% to $25.0. The company's market cap stands at $4.0 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALKS

ALMS

APLM

CTKB

FRES

GCTK

GRFS

HCWB

INCY

SNOA

TFFP

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

On Monday, Aclaris Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) entered into an exclusive license agreement with Biosion Inc for worldwide rights (excluding Greater China) to BSI-045B and BSI-502, a preclinical-stage, novel bispecific antibody directed against <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42034751/aclaris-therapeutics-announces-exclusive-global-license-agreement-with-biosion-inc-adding-potentia" rel="noreferrer noopener">both TSLP and IL4R</a>.
In a completed Phase 2a, single-arm, proof-of-concept trial in the United States in 22 patients with moderate to severe atopic dermatitis, BSI-045B was observed to have a pharmacodynamic, safety, and efficacy profile.
BSI-045B is also being advanced in multiple Phase 2 studies in China by Biosion&#8217;s regional partner, Chia Tai Tianqing Pharmaceutical Group, Co., Ltd. (CTTQ), targeting severe asthma and chronic rhinosinusitis with nasal polyps, accelerating the potential to show proof-of-concept across additional indications.
Under the terms of the agreement, Biosion shall receive over&nbsp;$40 million&nbsp;cash payment as an upfront license fee and reimbursement for certain development costs &amp; drug product materials.
Biosion shall also receive 19.9% shares of Aclaris Therapeutics.
Additional regulatory and sales milestone payments exceed&nbsp;$900 million, with tiered low-to-mid single-digit royalty payments based on a percentage of <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42036056/biosion-announces-exclusive-global-license-agreement-with-aclaris-therapeutics-on-two-potential-fi" rel="noreferrer noopener">annual net sales</a>.
Leerink Partners upgraded Aclaris from Market Perform to Outperform, with a price target of $7, <a target="_blank" href="https://www.benzinga.com/quote/ACRS/analyst-ratings" rel="noreferrer noopener">up from $2</a>.
The analyst writes, &#8220;Following completion of their strategic review, we expect investor focus to shift to ACRS&#8217; newly strengthened immunology-focused pipeline.&#8221;
Leerink writes that these updates mark a fresh start for Aclaris Therapeutics, with a clear strategic direction and promising catalysts in the next 6-12 months. This progress could reduce risks for BSI-045B and significantly enhance its value.
The analyst has updated the model to include BSI-045 B&#8217;s potential in atopic dermatitis (AD), estimating around $1.3 billion in revenue by 2035 with a 35% probability of success. The analyst also anticipates multiple Phase 2 trial results from China in asthma and chronic rhinosinusitis with nasal polyps, which could provide more insight into BSI-045 B&#8217;s potential.
Additionally, Leerink expects further progress in de-risking the company&#8217;s pipeline in the first half of next year.
BTIG upgrades Aclaris Therapeutics from Neutral to Buy and announces a $8 price target.
Price Action: ACRS stock is up 55.60% at $4.88 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42063475/interactive-strength-shares-jumps-premarket-as-saudi-fitness-chain-adopts-clmbr-machines" target="_blank" rel="noreferrer noopener">Interactive Strength Shares Jump As Saudi Fitness Chain Adopts CLMBR Machines: Details</a></li>
</ul>

Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/607ebdb217ff280001130e2a/julian-harrison">BTIG analyst Julian Harrison</a> upgraded the rating for Aclaris Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) from Neutral to Buy and announced a price target of $8. Aclaris Therapeutics shares closed at $3.14 on Monday. <a href="https://www.benzinga.com/quote/ACRS/analyst-ratings">See how other analysts view this stock.</a></li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/650428998345120001a2f3ec/wesley-brooks">HSBC analyst Wesley Brooks</a> upgraded the rating for QuantumScape Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) from Reduce to Hold and announced a price target of $5.3. QuantumScape shares closed at $4.73 on Monday. <a href="https://www.benzinga.com/quote/QS/analyst-ratings">See how other analysts view this stock.</a></li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5809e400846faa000106ad3a/cory-kasimov">Evercore ISI Group analyst Cory Kasimov</a> upgraded the rating for BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) from In-Line to Outperform and boosted the price target from $110 to $125. BioNTech shares closed at $101.87 on Monday. <a href="https://www.benzinga.com/quote/BNTX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity analyst Matthew Lee upgraded Bank of Nova Scotia (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BNS#TSX">BNS</a>) from Hold to Buy and raised the price target from C$71 to C$84. <a href="https://www.benzinga.com/quote/BNS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies analyst Roger Song upgraded the rating for Aclaris Therapeutics, Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) from Hold to Buy and raised the price target from $2 to $7. Aclaris Therapeutics shares closed at $3.14 on Monday. <a href="https://www.benzinga.com/quote/acrs/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying BNTX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="559" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19073934/image-195-1024x559.png" alt="" class="wp-image-654905" style="width:678px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19073934/image-195-1024x559.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19073934/image-195-300x164.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19073934/image-195-768x419.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19073934/image-195.png 1205w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42035732/jim-cramer-super-group-basic-materials-stock-is-very-hard-to-own-here">Jim Cramer: Super Group Finally &#8216;Broke Out,&#8217; This Basic Materials Stock Is &#8216;Very Hard To Own Here&#8217;</a></li>
</ul>

Pre-Market Outlook

ACHR

ACNB

BNTX

TSX:BNS

This BioNTech Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Leerink Partners analyst Thomas Smith upgrades Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) from Market Perform to Outperform and raises the price target from $2 to $7.

Leerink Partners Upgrades Aclaris Therapeutics to Outperform, Raises Price Target to $7

Jefferies analyst Roger Song upgrades Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) from Hold to Buy and raises the price target from $2 to $7.

Jefferies Upgrades Aclaris Therapeutics to Buy, Raises Price Target to $7

WIIM

Aclaris Therapeutics shares are trading higher after Piper Sandler upgraded the stock from Neutral to Overweight and raised its price target from $3 to $13. Also, BTIG upgraded the stock from Neutral to Buy and announced a price target of $8.

BTIG analyst Julian Harrison upgrades Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) from Neutral to Buy and announces $8 price target.

BTIG Upgrades Aclaris Therapeutics to Buy, Announces $8 Price Target

Piper Sandler analyst Christopher Raymond upgrades Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) from Neutral to Overweight and raises the price target from $3 to $13.

Piper Sandler Upgrades Aclaris Therapeutics to Overweight, Raises Price Target to $13

Aclaris Therapeutics Shares Spike Higher; Piper Sandler Upgrades Stock To Overweight With $13 Target Following Biosion Deal; Highlights Pipeline For Atopic Dermatitis And I&I Market, Catalysts Expected In 2025 Trials

Aclaris Therapeutics shares are trading higher after the company announced it entered into an exclusive license agreement with Biosion for worldwide rights to BSI-045B. The company announced an $80 million private placement.

Aclaris Therapeutics Secures $80M Through Private Placement Of 35.56M Shares At $2.25 Per Share; Funds To Support Pipeline Development And General Corporate Purposes

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion For Worldwide Rights (Excluding Greater China) To BSI-045B

Aclaris Had Aggregate Cash, Cash Equivalents And Marketable Securities Of $173.4M As Of September 30, Which Is Expected To Provide Cash Runway Into 2028

Press Releases

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets

This Healthcare Stock is Soaring Following Exclusive License Agreement Announcement

Peraso Inc. (NASDAQ: PRSO): Intro-Act Targets $3.30 Per Share After Positive Q3 Performance see more stocks inside….

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

Aclaris Therapeutics to Participate in Two March Healthcare Conferences

ALCE

PRSO

QUBT

TRNR

Aardvark Therapeutics, Inc. - Common Stock

Aardvark Therapeutics

Alumis

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals

Alto Neuroscience

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics

Atea Pharmaceuticals, Inc. - common stock

Atea Pharmaceuticals

Bioage Labs

Biote

Contineum Therapeutics, Inc. - Common stock

Contineum Therapeutics

Journey Medical Corporation - Common Stock

Journey Medical

Esperion Therapeutics, Inc. - Common Stock

Esperion Therapeutics

Fulcrum Therapeutics, Inc. - Common Stock

Fulcrum Therapeutics

MBX Biosciences

Milestone Pharmaceuticals Inc. - Common Shares

Milestone Pharmaceuticals

Nektar Therapeutics

Neumora Therapeutics, Inc. - Common Stock

Neumora Therapeutics

Rapport Therapeutics, Inc. - Common Stock

Rapport Therapeutics

Cassava Sciences

scPharmaceuticals

Septerna

Telomir Pharmaceuticals, Inc. - Common Stock

Telomir Pharmaceuticals

Terns Pharmaceuticals, Inc. - Common Stock

Terns Pharma

Third Harmonic Bio

Ventyx Biosciences

Zhengye Biotechnology Holding Limited - Ordinary Shares

Zhengye Biotechnology

Scotiabank

HC Wainwright & Co.

Leerink Partners

Jefferies

BTIG

월요일에 아클라리스 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>)는 바이오시온(Biosion Inc)과 TSLP 및 IL4R 모두에 대한 전임상 단계의 새로운 이중특이적 항체인 <a href="https://www.benzinga.com/pressreleases/24/11/g42034751/aclaris-therapeutics-announces-exclusive-global-license-agreement-with-biosion-inc-adding-potentia" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">BSI-045B 및 BSI-502</a>에 대한 전 세계 권리(중화권 제외)에 대한 독점 라이센스 계약을 체결했다. 이 회사의 주식은 화요일 46% 이상 급등했다.
미국에서 중증 아토피 피부염 환자 22명을 대상으로 진행된 2a 단계 단일군 개념 증명 시험에서 BSI-045B의 약리학적 동태, 안전성 및 효능 프로필이 관찰되었다.
BSI-045B는 또한 바이오시온의 지역 파트너인 치아 타이 텐칭 제약 그룹(Chia Tai Tianqing Pharmaceutical Group, Co., Ltd.) (CTTQ)에 의해 중국에서 중증 천식 및 비강 폴립이 있는 만성 비염을 대상으로 여러 2단계 연구에서 진행되고 있다. 이는 추가 적응증에서 개념 증명의 가능성을 가속화한다.
이 계약 조건에 따라, 바이오시온은 4천만 달러 이상의 현금 지급을 선불 라이센스료 및 특정 개발 비용 및 의약품 자재에 대한 상환으로 받을 것이다.
바이오시온은 또한 아클라리스 테라퓨틱스의 19.9% 주식을 받을 것이다.
추가적인 규제 및 판매 이정표 지급은 9억 달러를 초과하며, <a href="https://www.benzinga.com/pressreleases/24/11/n42036056/biosion-announces-exclusive-global-license-agreement-with-aclaris-therapeutics-on-two-potential-fi" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">연간 순매출</a>의 일정 비율에 따른 중간 저단계 로열티 지급이 포함되어 있다.
리링크 파트너스(Leerink Partners)는 아클라리스를 시장 수행에서 아웃퍼폼으로 상향 조정하였으며, 목표 주가를 7달러로 설정하였고, 이는 <a href="https://www.benzinga.com/quote/ACRS/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">2달러에서 상향 조정</a>된 것이다.
이 애널리스트는 &#8220;전략 검토 완료 후 투자자의 관심이 ACRS의 새롭게 강화된 면역학 중심 파이프라인으로 이동할 것으로 예상한다&#8221;고 작성했다.
리링크는 이러한 업데이트가 아클라리스 테라퓨틱스의 새로운 시작을 나타내며, 명확한 전략적 방향과 향후 6-12개월 내의 유망한 촉매제를 갖추었다고 언급했다. 이러한 진전은 BSI-045B에 대한 위험을 줄이고 그 가치를 상당히 향상시킬 수 있다.
이 애널리스트는 모델을 업데이트하여 BSI-045B의 아토피 피부염(AD) 잠재력을 포함시켰고, 2035년까지 약 13억 달러의 매출을 예상하며, 성공 확률은 35%로 추정했다. 이 애널리스트는 또한 중국에서 천식 및 만성 비염에 대한 여러 2단계 임상시험 결과를 예상하고 있으며, 이는 BSI-045B의 잠재력에 대한 더 많은 통찰력을 제공할 수 있다.
추가적으로, 리링크은 내년 상반기 이 회사 파이프라인의 리스크 축소에 대한 추가 진전을 예상하고 있다.
BTIG는 아클라리스 테라퓨틱스를 중립에서 매수로 상향 조정하고, 목표 주가를 8달러로 발표했다.
가격 변동: 아클라리스의 주식은 화요일 46.18% 급등한 4.59달러로 마감했다.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Aclaris Therapeutics

뉴스

에 대한 최신 뉴스 Aclaris Therapeutics (NASDAQ:ACRS) 주식

화요일, 11월 19, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌